[HTML][HTML] Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2)

R Seifert, L Emmett, SP Rowe, K Herrmann… - European Urology, 2023 - Elsevier
Context Prostate-specific membrane antigen (PSMA) targeting positron emission
tomography (PET) is emerging to become a reference imaging tool for the staging and …

Artificial intelligence and machine learning in nuclear medicine: future perspectives

R Seifert, M Weber, E Kocakavuk, C Rischpler… - Seminars in nuclear …, 2021 - Elsevier
Artificial intelligence and machine learning based approaches are increasingly finding their
way into various areas of nuclear medicine imaging. With the technical development of new …

First results on kinetic modelling and parametric imaging of dynamic 18F-FDG datasets from a long axial FOV PET scanner in oncological patients

H Sari, C Mingels, I Alberts, J Hu, D Buesser… - European journal of …, 2022 - Springer
Purpose To investigate the kinetics of 18 F-fluorodeoxyglucose (18 F-FDG) by positron
emission tomography (PET) in multiple organs and test the feasibility of total-body …

PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis

R Seifert, K Kessel, K Schlack, M Weber… - European Journal of …, 2021 - Springer
Abstract Introduction [177 Lu] Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging
treatment option for patients with end-stage prostate cancer. However, response to Lu …

[HTML][HTML] Analysis of PSMA expression and outcome in patients with advanced prostate cancer receiving 177Lu-PSMA-617 radioligand therapy

R Seifert, K Seitzer, K Herrmann, K Kessel… - Theranostics, 2020 - ncbi.nlm.nih.gov
Abstract Rationale: PSMA-PET-CT enables measuring molecular expression of prostate-
specific membrane antigen (PSMA) in vivo, which is the target molecule of 177 Lu-PSMA …

[HTML][HTML] Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs

C Miller, J Rousseau, CF Ramogida, A Celler… - Theranostics, 2022 - ncbi.nlm.nih.gov
Theranostics is an emerging paradigm that combines imaging and therapy in order to
personalize patient treatment. In nuclear medicine, this is achieved by using …

Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international …

A Gafita, I Rauscher, M Weber… - Journal of Nuclear …, 2022 - Soc Nuclear Med
Our objective was to develop version 1.0 of a novel framework for response evaluation
criteria in prostate-specific membrane antigen (PSMA) PET/CT (RECIP) and a composite …

A prognostic risk score for prostate cancer based on PSMA PET–derived organ-specific tumor volumes

R Seifert, S Rasul, K Seitzer, M Eveslage… - Radiology, 2023 - pubs.rsna.org
Background Prostate-specific membrane antigen (PSMA) PET has high specificity in
localizing primary tumors and metastases in patients with prostate cancer, but the individual …

Targeting PSMA revolutionizes the role of nuclear medicine in diagnosis and treatment of prostate cancer

WI Luining, MCF Cysouw, D Meijer, NH Hendrikse… - Cancers, 2022 - mdpi.com
Simple Summary Imaging plays a crucial role in the accurate staging of prostate cancer.
Prostate-specific membrane antigen (PSMA) is overexpressed in prostate cancer cells, and …

Machine learning-based radiomics for multiple primary prostate cancer biological characteristics prediction with 18F-PSMA-1007 PET: comparison among different …

F Yao, S Bian, D Zhu, Y Yuan, K Pan, Z Pan, X Feng… - La radiologia …, 2022 - Springer
Background PET-based radiomics features could predict the biological characteristics of
primary prostate cancer (PCa). However, the optimal thresholds to predict the biological …